Frank A. Laws, M.D.
, and Richard W. Smalling, M.D., Ph.D.
Dr. Laws is a Fellow in the Department of Internal Medicine, Division of Cardiology, University of Texas-Houston Medical School.
Dr. Laws reports no commercial conflict of interest. Dr. Smalling has received grant/research support from Centocor/Boston Scientific within the last three years.
This activity is made possible by an unrestricted educational grant from the Novartis Foundation for Gerontology.
Estimated time to complete:
Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Upon completion of this Cyberounds®
, you should be able to:
- Identify why blockade of the renin-angiotensin aldosterone system (RAAS) confers a beneficial effect in patients with congestive heart failure
- Identify pathways involved in the production of angiotensin-II and receptors that mediate the effects of angiotensin-II
- List the objectives of ongoing clinical trials assessing the role of ARBs in the treatment of patients with congestive heart failure.